TME Pharma Provides Results of First Exercise of Warrants Z
479,624 Warrants Z were exercised resulting in the issuance of 599,530 new ordinary shares Outstanding 3,326,104 War…
479,624 Warrants Z were exercised resulting in the issuance of 599,530 new ordinary shares Outstanding 3,326,104 War…
The exercise of Warrants Z follows a successfully completed capital increase with preferential subscription rights throu…
Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear road…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
€1.48 million private placement secured from a group of new investors Buyback will mark the end of TME Pharma's converti…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
Constructive meeting held with FDA provided feedback and clear guidance on key aspects of further development of NOX…
. Median overall survival surpasses 19 months and continues to improve in glioblastoma patients receiving NOX-A12 comb…
Transaction raised the full amount of €2.7 million leading to the issuance of 10.8 million new shares Strong demand prim…
This information is not intended for residents of the United Kingdom, United States, Australia, Canada or Japan. See Ann…